Moreover, in an investigation involving 12 patients with stage IIA-IIIB NSCLC undergoing neoadjuvant ALK-TKI therapy, a notable ORR of 91.7% and a major pathological response rate of 75.0% were documented. This evidence concerns the gene ALK and non-small cell lung carcinoma.